<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00455546</url>
  </required_header>
  <id_info>
    <org_study_id>AN-CVD-2221</org_study_id>
    <nct_id>NCT00455546</nct_id>
  </id_info>
  <brief_title>PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease</brief_title>
  <acronym>PLASMA</acronym>
  <official_title>PLASMA Trial: Phospholipase Levels And Serological Markers of Atherosclerosis: A Dose-Response Clinical Pharmacology Study of A-002 In Subjects With Stable Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anthera Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anthera Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be conducted at up to 80 centers worldwide and will be a double-blind
      randomized parallel group placebo controlled study among subjects with stable coronary artery
      disease (CAD). Subjects will be randomized to receive either placebo tablets or one of 4
      orally active doses of A-002. The duration of study drug therapy will be 8 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A-002 represents a novel therapy for the treatment of atherosclerosis and coronary artery
      disease (CAD). Through the inhibition of activity A-002 may provide multifunctional activity
      directed against key facets of the disease process, namely a) inflammation, b) atherogenic
      lipid profiles and c) the atherosclerotic process. Non-clinical and clinical data from recent
      studies have demonstrated the benefit of early and aggressive anti-inflammatory therapy to
      reduce cardiovascular risk. Recent clinical studies have provided a strong association
      between levels and cardiovascular event risk. The proposed Phase 2 clinical pharmacology
      study (Study No. AN-CVD-2221) will examine the effects of 4 different doses of A-002 compared
      with placebo, on enzyme levels and activity after 8 weeks of treatment. In addition, the
      effect of treatment on inflammatory markers of cardiovascular risk (C-reactive protein
      [CRP]), lipid levels and lipoprotein subclasses and other soluble biomarkers (e.g., ICAM-1,
      VCAM-1, TNF, MCP-1 etc) will also be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date>September 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of active and placebo treatments with respect to change from Baseline to Week 8 in sPLA2 levels and activity.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of active and placebo treatments with respect to change in: Inflammatory markers, lipid and biochemical parameters, and LDL and HDL subclasses.</measure>
  </secondary_outcome>
  <enrollment type="Actual">400</enrollment>
  <condition>Coronary Artery Disease (CAD)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A-002</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects are eligible for inclusion if they meet the following inclusion criteria:

          -  Men and women &gt; 18 years of age

          -  Written informed consent from the subject

          -  Stable CAD

          -  Stable medical condition, will be compliant and able to comply with the requirements
             of the protocol

        Exclusion Criteria:

          -  Subjects must NOT meet any of the following exclusion criteria:

          -  Planned CABG

          -  Hospitalization for acute coronary syndrome if troponin level is &gt;0.1 ng/mL in the
             preceding 6 weeks

          -  Hospitalization for ST-segment acute myocardial infarction (STEMI) in the preceding 12
             weeks

          -  Subjects with chronic inflammatory disease (e.g., RA), inflammatory bowel disease,
             recent (12 weeks) systemic or localized infection (the latter requiring clinical
             intervention), or major surgery

          -  hs-CRP &gt;15 mg/L repeated on at least 2 occasions &gt;24 hours apart due to
             non-cardiovascular systemic inflammatory conditions (e.g., rheumatoid disease)

          -  Acute or chronic heart failure as defined by the NYHA classification as functional
             Class III or Class IV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mobile Heart Specialists</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sonoran Health Specialists</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Arkansas Research</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward General Medical Center</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hudson</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Cardiovascuar Research</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>339521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cardiovascular Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta Cardiology Clinic, PC</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisville Cardiology Medical Group</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Research Associates</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Medical Associates</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Research, Inc.</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology, PC</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cardiovascular and Hypertension Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Black Hills Clinical Research Center</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Heart</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiopulmonary Research Science and Technology Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winsconin Heart, SC</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strazhesko Institute of Cardiology AMS</name>
      <address>
        <city>Kyiv</city>
        <state>03680</state>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovs'k State Medical Academy</name>
      <address>
        <city>Dnepropetrovs'k</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Therapy of AMS</name>
      <address>
        <city>Kharkiv</city>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital &quot;Ukrzaliznysti&quot;</name>
      <address>
        <city>Khirkov</city>
        <zip>61018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strazhesko Institute of Cardiology AMS</name>
      <address>
        <city>Kviv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kiev Central Hospital #1</name>
      <address>
        <city>Kyiv</city>
        <zip>01023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No 12</name>
      <address>
        <city>Kyiv</city>
        <zip>01103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Centre of Endocrine Surgery</name>
      <address>
        <city>Kyiv</city>
        <zip>02175</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strazhesko Institute of Cardiology AMS</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Gerontology AMS</name>
      <address>
        <city>Kyiv</city>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Gerontology</name>
      <address>
        <city>Kyiv</city>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L'viv Regional State Clinical Treatment and Diagnostics</name>
      <address>
        <city>L'viv</city>
        <zip>79015</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of &quot;Radioprylad&quot; Plant</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69108</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2007</study_first_submitted>
  <study_first_submitted_qc>March 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2007</study_first_posted>
  <last_update_submitted>February 1, 2010</last_update_submitted>
  <last_update_submitted_qc>February 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2010</last_update_posted>
  <keyword>Coronary</keyword>
  <keyword>Artery</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Phospholipase</keyword>
  <keyword>CAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varespladib methyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

